Literature DB >> 15843398

Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo.

Simon C Warby1, Edmond Y Chan, Martina Metzler, Lu Gan, Roshni R Singaraja, Susan F Crocker, Harold A Robertson, Michael R Hayden.   

Abstract

Huntington disease (HD) results from polyglutamine expansion in the huntingtin protein (htt). Despite the widespread tissue expression pattern of htt, neuronal loss is highly selective to medium spiny neurons of the striatum. Huntingtin is phosphorylated on serine-421 (S421) by the pro-survival signaling protein kinase Akt (PKB) and this has been previously shown to be protective against the toxicity of polyglutamine-expanded htt in cell culture. Using an antibody specific for htt phosphorylated on S421, we now demonstrate that htt phosphorylation is present at significant levels under normal physiological conditions in human and mouse brain. Furthermore, htt phosphorylation shows a regional distribution with the highest levels in the cerebellum, less in the cortex, and least in the striatum. In cell cultures and in YAC transgenic mice, the endogenous phosphorylation of polyglutamine-expanded htt is significantly reduced relative to wild-type htt. The presence and pattern of significant htt phosphorylation in the brain indicates that this dynamic post-translational modification is important for the regulation of htt and may contribute to the selective neurodegeneration seen in HD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15843398     DOI: 10.1093/hmg/ddi165

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  45 in total

Review 1.  Huntington's Disease and Mitochondria.

Authors:  Mohammad Jodeiri Farshbaf; Kamran Ghaedi
Journal:  Neurotox Res       Date:  2017-06-21       Impact factor: 3.911

2.  The role of post-translational modifications of huntingtin in the pathogenesis of Huntington's disease.

Authors:  Yan Wang; Fang Lin; Zheng-Hong Qin
Journal:  Neurosci Bull       Date:  2010-04       Impact factor: 5.203

Review 3.  Energy deficit in Huntington disease: why it matters.

Authors:  Fanny Mochel; Ronald G Haller
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

4.  Disease-toxicant screen reveals a neuroprotective interaction between Huntington's disease and manganese exposure.

Authors:  B Blairanne Williams; Daphne Li; Michal Wegrzynowicz; Bhavin K Vadodaria; Joel G Anderson; Gunnar F Kwakye; Michael Aschner; Keith M Erikson; Aaron B Bowman
Journal:  J Neurochem       Date:  2009-10-21       Impact factor: 5.372

Review 5.  Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease.

Authors:  Dagmar E Ehrnhoefer; Liza Sutton; Michael R Hayden
Journal:  Neuroscientist       Date:  2011-02-10       Impact factor: 7.519

Review 6.  Repeat expansion disease: progress and puzzles in disease pathogenesis.

Authors:  Albert R La Spada; J Paul Taylor
Journal:  Nat Rev Genet       Date:  2010-04       Impact factor: 53.242

7.  NMDA receptor excitotoxicity: impact on phosphatase activity and phosphorylation of huntingtin.

Authors:  Michael R Jablonski; Lori Cooper; Dena A Jacob
Journal:  J Neurosci       Date:  2011-03-23       Impact factor: 6.167

Review 8.  Animal models of polyglutamine diseases and therapeutic approaches.

Authors:  J Lawrence Marsh; Tamas Lukacsovich; Leslie Michels Thompson
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

9.  Serine 421 regulates mutant huntingtin toxicity and clearance in mice.

Authors:  Ian H Kratter; Hengameh Zahed; Alice Lau; Andrey S Tsvetkov; Aaron C Daub; Kurt F Weiberth; Xiaofeng Gu; Frédéric Saudou; Sandrine Humbert; X William Yang; Alex Osmand; Joan S Steffan; Eliezer Masliah; Steven Finkbeiner
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

10.  Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease.

Authors:  Jose R Pineda; Raúl Pardo; Diana Zala; Hua Yu; Sandrine Humbert; Frédéric Saudou
Journal:  Mol Brain       Date:  2009-10-27       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.